Daridorexant, a new drug against chronic insomnia


Insomnia is persistent difficulty starting or maintaining quality sleep.

It is a very frequent pathology in the general population, it is estimated that between 25 and 35% of adults have suffered occasional or transient insomnia, while between 10 and 15% suffer from chronic insomnia. For these latter cases, the arrival of a new drug on the market seems to offer a solution, and an alternative to hypnotic sedatives such as benzodiazepines (Valium, Xanax or Clonazepam).

Daridorexant, a drug developed and manufactured by Switzerland-based Idorsia Pharmaceuticals. It belongs to a class of drugs known as dual orexin receptor antagonists. In January 2022, it received approval from the US Food and Drug Administration (FDA) to treat chronic insomnia in adults, and will be marketed as of May under the name QUVIVIQ.

This decision was reached after knowing the results of the phase 3 trials, published in The Lancet Neurologywhich enrolled 1,854 adults aged 18 years and older with insomnia at 154 clinical trial sites, in 17 countries.

The research consisted of participants receiving Daridorexant, in doses of 10, 25 or 50 mg, or a placebo, once a day (in the evening), for 3 months. Criteria for treatment efficacy were change from baseline to month 1 and month 3 in measures to assess sleep quality: Latency to Persistent Sleep and Wake After Sleep Onset, objectively controlled by polysomnography in a sleep laboratory .

Table of Contents

See also  Fatigue, palpitations and anxiety: post covid symptoms can last for months

  • Natural remedies to sleep well and avoid insomnia

After completion of the treatment period, the investigators found that the 25 and 50 mg doses showed a statistically significant improvement in measurements versus placebo at both month 1 and month 3. However, the 10 mg dose did not show significant improvements in measurements, so it was not approved by the FDA.

The 50 mg dose also showed a significant reduction in daytime sleepiness compared to placebo.

Other works, such as those published in neurology, Psychopharmacology Y sleeping, also showed positive results after analyzing the effects of Daridorexant in people with chronic insomnia. They detailed that Daridorexant is a safe drug that does not generate tolerance and does not cause drowsiness the next day.

How does Daridorexant work?

Daridorexant is used to treat chronic insomnia by solely blocking the activation of orexin receptors, a hormone that keeps us awake. This allows sleep to occur, keeping its structure intact in all its phases.

This is a big difference from traditional sleep aids such as benzodiazepines, which cause extensive inhibition of brain activity, shortening the time it takes to fall asleep, prolonging the time spent asleep, and generally reducing wakefulness.

However, its use tends to worsen sleep quality by increasing light sleep and decreasing deep sleep. Another disadvantage of benzodiazepines is possible tolerance to their effects, reduced slow-wave sleep, and the fact that withdrawal is characterized by rebound insomnia and a prolonged period of anxiety and agitation.

See also  Oscar Mayer launches a face mask inspired by Bologna and no, I'm not kidding

In addition, due to the risk of generating dependency, the use of benzodiazepines is usually recommended only for a period of two to four weeks, unlike Daridorexant, which was tested for months in the participants of the different investigations.

The recommended dose of Daridorexant is one 50 mg tablet to be taken orally at night, about 30 minutes before bedtime. For patients with moderate hepatic impairment or those taking other medicines, for example moderate inhibitors of CYP3A4 (an enzyme produced by the body), the recommended dose is 25 mg per night.

Is it safe to take Daridorexant?

The approval and marketing of Daridorexant generated a revolution in certain scientific and media circles, since it is easy to take, appears to be safe, does not generate tolerance and does not cause drowsiness the next day.

In turn, these results are supported by studies of good quality, with significant samples of participants, although with a tendency to concentrate more on older adults. Despite this effectiveness, many experts agree that the new drug should be treated with caution.

As it is a new treatment, its long-term effects are still unknown. Headaches, hallucinations, drowsiness, dizziness, sleep paralysis, nausea and fatigue were reported in the investigations, albeit infrequently).

See also  A 106-year-old woman includes Big Macs as part of her longevity diet

Another aspect is the interaction with other medications. The doctor is the one who will evaluate in each case if the new drug is an alternative for a person suffering from insomnia.

Other solutions

Specialists in sleep problems point out that taking a medication is not a definitive solution. It is necessary to work on the factors that generate lack of sleep, which affects millions of people in the world. In this sense, cognitive therapy has been shown to be effective in many cases of chronic insomnia.

Managing stress is another step to improve sleep quality, and to achieve this, adopting a healthy lifestyle is essential. This should include:

  • A balanced diet, rich in vegetable fruits, cereals and legumes.
  • Exercise regularly.
  • Maintain sleep schedules (go to bed and wake up at the same time every day).
  • Try to make the sleeping environment as pleasant as possible.
  • Avoid electronic devices before bed.
  • Do not eat or drink excessively at night.
  • Learn to recognize and handle stressful situations. For this, relaxation techniques or practices, such as yoga, deep breathing or meditation can be very useful.
  • Sources consulted: American Academy of Sleep Medicine, US National Library of Medicine, Mayo Clinic, SleepFoundation.





Leave a Comment

Your email address will not be published.